FGFR3 INHIBITOR COMPOUNDS

The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	METCALF, Andrew Terrance, WALLS, Shane Michael, CONDROSKI, Kevin Ronald, DILGER, Andrew Karl, ABRAHAM, Adedoyin David, KERCHER, Timothy Scott, URKALAN, Kaveri Balan, HAZLITT, Robert Alan, BUME, Desta Doro
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer. La présente invention concerne des composés de formule : destinés à être utilisés dans le traitement de la sclérodermie généralisée, de la fibrose (par exemple, la fibrose pulmonaire), l'achondroplasie, la dysplasie thanatophore (par exemple, de type I), l'achondroplasie sévère avec un retard de développement et une acanthosis nigricans (SADDAN), le syndrome de Muenke ou le cancer.